相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia.
John C. Byrd et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus
Damien Blez et al.
HAEMATOLOGICA (2020)
Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections
Rossana Maffei et al.
BLOOD REVIEWS (2020)
Risk of Infection Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Somedeb Ball et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
Jan A. Burger et al.
LEUKEMIA (2020)
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients
Steven P. Treon et al.
BLOOD (2020)
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
John C. Byrd et al.
CLINICAL CANCER RESEARCH (2020)
Management of Ibrutinib Toxicities: a Practical Guide
Masa Lasica et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2020)
CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report
Tycho Baumann et al.
LEUKEMIA (2020)
The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice
Sameer A. Parikh et al.
CANCER MEDICINE (2020)
Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report
Antonio Cuneo et al.
BLOOD (2020)
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
Anthony R. Mato et al.
BLOOD (2020)
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
Lydia Scarfo et al.
LEUKEMIA (2020)
Reply to CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report Analysis of six hematological centers in Lombardy On behalf of CLL commission of Lombardy Hematology Network (REL)
Gianluigi Reda et al.
LEUKEMIA (2020)
Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors
Christine E. Ryan et al.
BLOOD ADVANCES (2020)
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab
John C. Byrd et al.
BLOOD (2019)
Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)
Georg Maschmeyer et al.
LEUKEMIA (2019)
Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies
Kerry A. Rogers et al.
LEUKEMIA (2019)
Probable Invasive Pulmonary Cryptococcosis and Possible Cryptococcal Empyema in CLL Treated With Frontline Ibrutinib
Amber B. Koehler et al.
MAYO CLINIC PROCEEDINGS (2019)
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
Constantine S. Tam et al.
BLOOD (2019)
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
T. D. Shanafelt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes
Tom Hofland et al.
JOURNAL OF IMMUNOLOGY (2019)
Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study
Rosa Ruchlemer et al.
MYCOSES (2019)
Atypical primary cutaneous cryptococcosis during ibrutinib therapy for chronic lymphocytic leukemia
Anna Maria Peri et al.
ANNALS OF HEMATOLOGY (2019)
How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia
Deborah M. Stephens et al.
BLOOD (2019)
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
Carol Moreno et al.
LANCET ONCOLOGY (2019)
Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis
Susan M. O'Brien et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies
Steven E. Coutre et al.
BLOOD ADVANCES (2019)
Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors
Marissa A. Zarakas et al.
CURRENT FUNGAL INFECTION REPORTS (2019)
Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies
AnnaLynn M. Williams et al.
LEUKEMIA & LYMPHOMA (2018)
Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib
David Ghez et al.
BLOOD (2018)
Risk of hepatitis B virus reactivation in patients treated with ibrutinib
Sarah P. Hammond et al.
BLOOD (2018)
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
Michael Hallek et al.
BLOOD (2018)
Ibrutinib blocks Btk-dependent NF-κB and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis
Amelia Bercusson et al.
BLOOD (2018)
Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice
John G. Gribben et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer
Tilly Varughese et al.
CLINICAL INFECTIOUS DISEASES (2018)
Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies
Benjamin F. Tillman et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
Ibrutinib and Aspergillus: a Btk-targeted risk
Jennifer A. Woyach
BLOOD (2018)
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
J. A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Disseminated herpes zoster in chronic lymphocytic leukemia (CLL) patients treated with B-cell receptor pathway inhibitors
Karthik V. Giridhar et al.
LEUKEMIA & LYMPHOMA (2017)
Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia
Mathias Lutz et al.
CANCER RESEARCH AND TREATMENT (2017)
Severe hepatitis B virus reactivation related to ibrutinib monotherapy
Yair Herishanu et al.
ANNALS OF HEMATOLOGY (2017)
Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib
Inhye E. Ahn et al.
BLOOD (2016)
Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system
Dennis W. Raisch et al.
EXPERT OPINION ON DRUG SAFETY (2016)
An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data
Michael Hallek
LANCET ONCOLOGY (2016)
Miliary tuberculosis after initiation of ibrutinib in chronic lymphocytic leukemia
Song-Yau Wang et al.
ANNALS OF HEMATOLOGY (2015)
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
Preetesh Jain et al.
BLOOD (2015)
Phagocytosis-dependent activation of a TLR9-BTK-calcineurin-NFAT pathway co-ordinates innate immunity to Aspergillus fumigatus
Susanne Herbst et al.
EMBO MOLECULAR MEDICINE (2015)
Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages
Mercedes Borge et al.
HAEMATOLOGICA (2015)
Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages
Mercedes Borge et al.
HAEMATOLOGICA (2015)
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
Kami J. Maddocks et al.
JAMA ONCOLOGY (2015)
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity
Holbrook E. Kohrt et al.
BLOOD (2014)
分享论文
